Elscint's second-quarter results sag It was a case of good newsand bad news this month for Elscint Ltd., which reported financialresults for the second quarter (end-June). On one hand, the Israelivendor reported that sales of its CT Twin family of
Elscint's second-quarter results sag It was a case of good newsand bad news this month for Elscint Ltd., which reported financialresults for the second quarter (end-June). On one hand, the Israelivendor reported that sales of its CT Twin family of scanners werestronger than expected. On the other, overall revenues for thequarter dropped 9% due to the ongoing slump in nuclear medicinesales in North America.
Revenues for the second quarter of 1994 totaled $54.7 million,down from the $60.3 million recorded in the same period last year.Net income was down sharply, to $2.7 million from $7.2 millionin last year's second quarter, a drop of 63%.
Depressed market conditions in North America have caused intensecompetition and aggressive pricing, which have impacted margins,according Shmuel Parag, president and CEO of Haifa-based Elscint.The nuclear medicine market is down 25% in the first two quartersof 1994, according to data from the National Electrical ManufacturersAssociation, Parag said.
The company saw a 10% increase in the order backlog for itsCT-Twin family, however. CT scanner sales, as well as cost-cuttingmeasures Elscint has already implemented, should improve the company'sresults beginning in the fourth quarter of this year.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.